Phase II study of combination of the HyperCVAD regimen with dasatinib in patients with Philadelphia chromosome (Ph) or BCR-ABL positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB)

被引：6

作者：

Ravandi, Farhad ^{[1
]}

Thomas, Deborah ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Faderl, Stefan ^{[1
]}

Koller, Charles ^{[1
]}

Brown, Devri ^{[1
]}

Garris, Rebecca ^{[1
]}

Borthakur, Gautam ^{[1
]}

Burger, Jan ^{[1
]}

Kebriaei, Partow ^{[1
]}

Jorgensen, Jeffrey ^{[1
]}

Jones, Dan ^{[1
]}

Cortes, Jorge ^{[1
]}

O'Brien, Susan ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.2814.2814

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2814

引用

页码：828A / 828A

页数：1

共 50 条

[31] Kinase domain point mutations in Ph plus acute lymphoblastic leukemia (ALL) and lymphoid blast crisis of chronic myeloid leukemia (CML) and their emergence following therapy with Bcr-Abl kinase inhibitors.
Jones, Dan
Luthra, Rayjalakshmi
Kantarjian, Hagop M.
Breeden, Megan
O'Brien, Susan
Faderl, Stefan
Cortes, Jorge
Thomas, Deborah
BLOOD, 2006, 108 (11) : 519A - 519A
[32] Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia
Swords, Ronan
Alvarado, Yesid
Giles, Francis
CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S113 - S119
[33] The existence of lymphoid lineage restricted Philadelphia chromosome-positive acute lymphoblastic leukemia with heterogeneous bcr-abl rearrangement
L Pajor
JA Vass
L Kereskai
P Kajtár
Á Szomor
M Egyed
J Iványi
P Jáksó
Leukemia, 2000, 14 : 1122 - 1126
[34] The existence of lymphoid lineage restricted Philadelphia chromosome-positive acute lymphoblastic leukemia with heterogeneous bcr-abl rearrangement
Pajor, L
Vass, JA
Kereskai, L
Kajtár, P
Szomor, A
Egyed, M
Iványi, J
Jáksó, P
LEUKEMIA, 2000, 14 (06) : 1122 - 1126
[35] Detection of resistance to STI571 in patients with BCR-ABL positive acute leukemia and chronic myeloid leukemia (CML) blast crisis.
Mahon, FX
Belloc, F
Cholet, C
Cony-Makhoul, P
Guilhot, F
Melo, JV
Berthaud, P
Reiffers, J
BLOOD, 2000, 96 (11) : 471A - 471A
[36] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in Imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph plus ALL).
Kantarjian, HM
Ottman, O
Cortes, J
Wassman, M
Wunderle, L
Bhalla, K
Jones, D
Hochhaus, A
Rae, P
Alland, L
Dugan, M
Albitar, M
Giles, F
BLOOD, 2005, 106 (11) : 15A - 16A
[37] AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in imatinib-resistant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoid leukemia (Ph plus ALL)
Kantarjian, HM
Ottmann, O
Hochhaus, A
Mueller, M
Cortes, J
Wassmann, B
Wunderle, L
Bhalla, K
Jones, D
Rafferty, T
Albitar, M
Rae, L
Dugan, M
Alland, L
Giles, F
ANNALS OF ONCOLOGY, 2006, 17 : 32 - 32
[38] Philadelphia chromosome positive acute myeloid leukemia or de novo chronic myeloid leukemia-blast phase?
Frankfurt, Olga
Platanias, Leonidas C.
LEUKEMIA & LYMPHOMA, 2013, 54 (01) : 1 - 2
[39] Dasatinib Efficacy in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Pre-Existing BCR-ABL Mutations
Mueller, Martin C.
Cortes, Jorge
Kim, Dong-Wook
Druker, Brian J.
Erben, Philipp
Pasquini, Ricardo
Hughes, Timothy P.
Matloub, Yousif
Ploughman, Lynn
Hochhaus, Andreas
BLOOD, 2008, 112 (11) : 171 - 172
[40] ANALYSIS OF BCR-ABL KINASE DOMAIN MUTATIONS IN HUNGARIAN PATIENTS WITH IMATINIB RESISTANT CHRONIC MYELOID LEUKEMIA AND PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA
Meggyesi, N.
Bors, A.
Halm, G.
Nahajevszky, S.
Barta, A.
Lueff, S.
Batai, A.
Remenyi, P.
Masszi, T.
Fekete, S.
Ujj, G.
Tordai, A.
Andrikovics, H.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 538 - 538

← 1 2 3 4 5 →